Comparative Pharmacology
Head-to-head clinical analysis: HC 1 versus LOCOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HC 1 versus LOCOID.
HC #1 vs LOCOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine production.
Hydrocortisone: 100-200 mg IV as initial dose, then 50-100 mg IV every 6 hours, or 0.18 mg/kg/h IV continuous infusion.
Topical: Apply a thin layer to affected area once or twice daily. Maximum: 30-60 g per week. Not for use >2 consecutive weeks or on >50% of body surface.
None Documented
None Documented
2–4 hours (terminal); prolonged in renal impairment.
Terminal elimination half-life: 30-40 hours; clinically significant for once-daily dosing and prolonged action
Renal: 90% as unchanged drug; fecal: 10%.
Renal (approximately 60-70%) as conjugated metabolites; biliary/fecal (approximately 20-30%)
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid